Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO and CAMBRIDGE (UK), April 21, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Nanna Therapeutics Limited (CEO: David Williams, Ph.D., “Nanna”) today announced that Astellas has acquired Nanna, a biotech...
TOKYO, April 10, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today a new drug application (NDA) for the oral once-daily therapy XOSPATA® (gilteritinib), for the treatment of adult patients...
TOKYO, April 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that three of its research and production facilities in Japan will be changing their electricity supply plan to the Aqua Premium1 plan...
TOKYO , April 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and BANDAI NAMCO Entertainment Inc. (President and CEO: Yasuo Miyakawa, “BANDAI NAMCO Entertainment”) today announced that the two...
SOUTH SAN FRANCISCO, CA and Tokyo, March 23, 2020 - CytomX Therapeutics, Inc. (NASDAQ: CTMX, President, Chief Executive Officer and Chairman: Sean McCarthy, D. Phil. “CytomX”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa...
TOKYO , March 18, 2020 - Gifu University (President: Hisataka Moriwaki M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the parties have established, inside Gifu University Graduate School...
TOKYO, February 27, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “the Company”) today announced that at the meeting of the Board of Directors held today...
TOKYO and BOTHELL, Wash., February 19, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
TOKYO and NEW YORK, February 11, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today results of the final overall survival (OS) analysis from the Phase 3 PROSPER trial, which...
BOTHELL, Wash. and TOKYO, February 10, 2020 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results from the phase 1b/2 clinical trial EV-103 in previously...
Follow us
